BACKGROUND: Ischemic stroke and transient ischemic attack can be difficult to diagnose clinically, and both acute and preventive therapies carry some risk. Serum biomarkers could increase diagnostic certainty by helping to distinguish cerebral ischemia from common mimics such as focal seizure, complicated migraine, and psychogenic spells. Biomarkers could also identify patients at high risk for future vascular events, which would aid in management decisions. REVIEW SUMMARY: There are many potential obstacles to finding these biomarkers, which are reviewed here, including the blood brain barrier, confounding by other conditions, and imperfect gold standards for use in validation. Diagnostic biomarkers are likely to be molecules found predominantly in brain tissue with rapid entry into the blood, whereas risk-stratification biomarkers may be related to the concept of an active atherosclerotic plaque. Many promising serum molecules have been examined in small series of patients with cerebrovascular disease. CONCLUSION: Large series examining many candidate molecules will be needed to find valid biomarkers, and this should be followed by use in future intervention trials to prove their utility.
BACKGROUND:Ischemic stroke and transient ischemic attack can be difficult to diagnose clinically, and both acute and preventive therapies carry some risk. Serum biomarkers could increase diagnostic certainty by helping to distinguish cerebral ischemia from common mimics such as focal seizure, complicated migraine, and psychogenic spells. Biomarkers could also identify patients at high risk for future vascular events, which would aid in management decisions. REVIEW SUMMARY: There are many potential obstacles to finding these biomarkers, which are reviewed here, including the blood brain barrier, confounding by other conditions, and imperfect gold standards for use in validation. Diagnostic biomarkers are likely to be molecules found predominantly in brain tissue with rapid entry into the blood, whereas risk-stratification biomarkers may be related to the concept of an active atherosclerotic plaque. Many promising serum molecules have been examined in small series of patients with cerebrovascular disease. CONCLUSION: Large series examining many candidate molecules will be needed to find valid biomarkers, and this should be followed by use in future intervention trials to prove their utility.
Authors: Giuseppe Sangiorgi; Alessandro Mauriello; Elena Bonanno; Claus Oxvig; Cheryl A Conover; Michael Christiansen; Santi Trimarchi; Vincenzo Rampoldi; David R Holmes; Robert S Schwartz; Luigi Giusto Spagnoli Journal: J Am Coll Cardiol Date: 2006-05-15 Impact factor: 24.094
Authors: J David Curb; Robert D Abbott; Beatriz L Rodriguez; Pamela Sakkinen; Jordan S Popper; Katsuhiko Yano; Russell P Tracy Journal: Circulation Date: 2003-04-07 Impact factor: 29.690
Authors: A Mauriello; G Sangiorgi; G Palmieri; R Virmani; D R Holmes; R S Schwartz; R Pistolese; A Ippoliti; L G Spagnoli Journal: Circulation Date: 2000-02-22 Impact factor: 29.690
Authors: N S Rost; P A Wolf; C S Kase; M Kelly-Hayes; H Silbershatz; J M Massaro; R B D'Agostino; C Franzblau; P W Wilson Journal: Stroke Date: 2001-11 Impact factor: 7.914
Authors: Timothy H Rainer; Lawrence K S Wong; Wynnie Lam; Eddie Yuen; Nicole Y L Lam; Constantine Metreweli; Y M Dennis Lo Journal: Clin Chem Date: 2003-04 Impact factor: 8.327
Authors: Linda Papa; Kimberly Rosenthal; Francesca Silvestri; John C Axley; Jared M Kelly; Stephen B Lewis Journal: Sci Rep Date: 2018-09-06 Impact factor: 4.379
Authors: L Servaas Dolmans; Frans H Rutten; Marie-Louise El Bartelink; Gerdien Seppenwoolde; Sanne van Delft; L Jaap Kappelle; Arno W Hoes Journal: BMC Neurol Date: 2015-07-28 Impact factor: 2.474